Last reviewed · How we verify
senfrol monotherapy
Senfrol monotherapy works by inhibiting the activity of a specific enzyme.
Senfrol monotherapy works by inhibiting the activity of a specific enzyme. Used for Type 2 diabetes.
At a glance
| Generic name | senfrol monotherapy |
|---|---|
| Sponsor | Peking University Third Hospital |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This inhibition leads to a decrease in the production of a certain molecule, resulting in therapeutic effects. The exact mechanism is complex and involves multiple pathways.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- senfrol monotherapy CI brief — competitive landscape report
- senfrol monotherapy updates RSS · CI watch RSS
- Peking University Third Hospital portfolio CI